Thermo Fisher Scientific

At a glance

Thermo Fisher Scientific reported 2025 revenue of $44.56B, up 3.9% from $42.88B in 2024. Over 4 years since 2021 ($39.21B), that is growth of about 3.2% a year. Operating margin was 17.4%, down from 25.6% in 2021. Revenue peaked in 2022 at $44.91B.

In the last 12 months 7 insiders reported 0 open-market purchases and 25 sales ($146M). 16 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $36.1M by Executive Vice President & COO Michel Lagarde on Dec 4, 2025.

Thermo Fisher Scientific filed 10 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (2), material agreement (2) and shareholder vote results (1). The latest officer or director change was reported on Oct 30, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

4 of the 20 investors tracked here held Thermo Fisher Scientific at the last quarter end, worth $1.4B combined. It is the largest weight for Viking Global Investors (2.8% of its portfolio), followed by National Pension Service (Korea) (0.3%). New this quarter: Duquesne Family Office. Added: Viking Global Investors and National Pension Service (Korea). Reduced: Bridgewater Associates.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.